RxDoctor Payments Data

David Harper, MD

Cardiovascular Disease · Dallas, TXNPI 1174550834

Payments from drug & device makers

$1,246in general payments, 2019–2025

Across 35 payments — averaging $35.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$303
  • Heartflow, Inc.$208
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$179
  • Medtronic$157
  • Pfizer$80
  • Actelion Pharmaceuticals US, Inc.$60
  • plus $258 from 10 others

What the payments were for

  • Food & beverage$1,19096%
  • Other$564%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,246 in reported general payments places this provider in the 25th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$458,354
Medicare patients
1,494
Services billed
5,359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban747$897,572
XareltoRivaroxaban182$216,799
JardianceEmpagliflozin64$86,523
EntrestoSacubitril/Valsartan59$77,972
Repatha SureclickEvolocumab21$19,993
Praluent PenAlirocumab20$16,656
Metoprolol Succinate590$9,356
BrilintaTicagrelor23$7,931
Atorvastatin Calcium522$5,208
Ranolazine ErRanolazine28$3,744
Valsartan97$3,059
Amlodipine Besylate476$2,551
Lisinopril279$2,355
Flecainide Acetate47$2,294
Rosuvastatin Calcium231$2,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$80$897,572747 claims
Boehringer IngelheimJardiance$11$86,52364 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →